

# CERTIFICATE OF ANALYSIS No.: 2022-10782

## CLIENT

Arktis Global LLP, 32 Kinburn Street  
SE16 6DW London, United Kingdom

## SAMPLE \*

















CBD DROPS 10,53%

Sample condition: SUITABLE  
Sample ID: 2252012  
Sample type: Viscous liquid  
Batch No.: \* DR10522361A

Work order: 2022-107193  
Analysis ID: 2022\_293  
Method ID: PHL\_RPC\_12C  
Method SOP: MET-LAB-001-06

Sample received: 27/12/2022  
Start of analysis: 28/12/2022  
End of analysis: 29/12/2022  
Analyst: Domen Lavriha

\* Information provided by the client.

CANNABINOID PROFILE	Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
<b>CBDV</b> - Cannabidivarin	0.139	0.025	
<b>CBDA</b> - Cannabidiolic acid	< LOQ	n/a	
<b>CBGA</b> - Cannabigerolic acid	< LOQ	n/a	
<b>CBG</b> - Cannabigerol	0.518	0.067	
<b>CBD</b> - Cannabidiol	10.74	0.54	
<b>THCV</b> - Tetrahydrocannavarin	< LOQ	n/a	
<b>CBN</b> - Cannabinol	< LOQ	n/a	
<b>Δ<sup>9</sup>-THC</b> - Δ-9-Tetrahydrocannabinol	< LOQ	n/a	
<b>Δ<sup>8</sup>-THC</b> - Δ-8-Tetrahydrocannabinol	< LOQ	n/a	
<b>CBL</b> - Cannabicyclol	< LOQ	n/a	
<b>CBC</b> - Cannabichromene	< LOQ	n/a	
<b>Δ<sup>9</sup>-THCA</b> - Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	
<b>CBE</b> - Cannabielsoin	n/a #	n/a	
<b>CBV</b> - Cannabivarin	n/a #	n/a	
<b>CBCA</b> - Cannabichromenic acid	n/a #	n/a	
<b>CBT</b> - Cannabicitran	n/a #	n/a	

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.

The results given herein apply only to the sample as received and tested. **Expanded Uncertainty** was calculated using coverage factor  $k = 2$ , corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

29/12/2022

Approved by:



mag. Janja Ahej  
Analytical Laboratory Manager

Authorized by:



dr. Boštjan Jančar  
Chief Technology Officer

End of Certificate